Lifecare reaffirms positive CGM study results, addresses media concerns

Lifecare ASA announced that the second subject in its LFC-SEN-002 veterinary longevity study reconfirmed positive findings regarding the safety, biocompatibility, and suitability for long-term use of its next-generation continuous glucose monitoring (CGM) technology. This builds on previous human study data (LFC-SEN-001) that showed accurate glucose measurement on par with commercial systems. The ongoing study focuses on product development, with additional subjects planned for enrolment to further validate glucose measurement in healthy and diabetic animals.

Histopathological analyses after 90 days of implantation confirmed the device was well-tolerated, showing only mild localized tissue reactions without adverse events, reinforcing its safety for long-term implantation. Lifecare has resubmitted its protocol to continue the study beyond the current August expiration, as it plans to extend the study until formally defined end.

In response to recent media coverage deemed speculative and inaccurate, Lifecare will file a formal complaint with the Norwegian Press Complaints Commission (PFU) to safeguard shareholder trust and ensure accurate market information. The company emphasizes its commitment to transparent communication and its belief in its technology's potential to deliver meaningful innovation for diabetes management.